APA (7th ed.) Citation

O, W., H, L., G, W., X, S., T, B., MA, S., . . . E, M. (2024). Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial. JAMA neurology, 81(6), 582. https://doi.org/10.1001/jamaneurol.2024.0991

Chicago Style (17th ed.) Citation

O, Wagemann, et al. "Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial." JAMA Neurology 81, no. 6 (2024): 582. https://doi.org/10.1001/jamaneurol.2024.0991.

MLA (9th ed.) Citation

O, Wagemann, et al. "Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial." JAMA Neurology, vol. 81, no. 6, 2024, p. 582, https://doi.org/10.1001/jamaneurol.2024.0991.